Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer [1] [2] [3] [4] [5] . In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote resistance to T cell checkpoint inhibitors [1] [2] [3] [4] [5] [6] [7] . Here we show that macrophage PI 3-kinase γ controls a critical switch between immune stimulation and suppression during inflammation and cancer. PI3Kγ signalling through Akt and mTOR inhibits NFκB activation while stimulating C/EBPβ activation, thereby inducing a transcriptional program that promotes immune suppression during inflammation and tumour growth. By contrast, selective inactivation of macrophage PI3Kγ stimulates and prolongs NFκB activation and inhibits C/EBPβ activation, thus promoting an immunostimulatory transcriptional program that restores CD8 + T cell activation and cytotoxicity. PI3Kγ synergizes with checkpoint inhibitor therapy to promote tumour regression and increased survival in mouse models of cancer. In addition, PI3Kγ-directed, anti-inflammatory gene expression can predict survival probability in cancer patients. Our work thus demonstrates that therapeutic targeting of intracellular signalling pathways that regulate the switch between macrophage polarization states can control immune suppression in cancer and other disorders.
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We investigated the association between immune responses and survival in primary tumours from human papilloma virus (HPV) + (n = 97) and HPV − (n = 423) head and neck squamous cell carcinoma (HNSCC) cohorts from the Cancer Genome Atlas 8, 9 . High expression levels of pro-inflammatory mRNAs IL12A, IL12B, IFNG and CD8A were associated with increased survival in HPV + but not HPV − cohorts, whereas high expression of IL6 was negatively associated with survival (Extended Data Fig. 1a-e) . HPV + patients with this favourable immune expression profile (n = 35) had 97% survival at 3 years compared with 57% survival for patients without this profile (n = 62) (Fig. 1a) . Similar associations were observed in lung adenocarcinoma and gastric carcinoma patients (Extended Data Fig. 1f, g ). These results suggest that therapeutic approaches that stimulate proinflammatory gene expression might enhance cancer patient survival.
We hypothesized that macrophage signalling pathways, such as those regulated by the class IB isoform PI3Kγ , might control the switch between immune stimulation and suppression in inflammation and cancer. PI3Kγ is abundantly expressed in myeloid cells but not in cancer cells [10] [11] [12] [13] (Extended Data Fig. 1h ) and promotes myeloid cell trafficking during inflammation and cancer [12] [13] [14] [15] [16] . Mice lacking PI3Kγ (Pik3cg Fig. 1l ). PI3Kγ inhibition did not directly affect the growth or survival of tumour cells, which do not express the kinase [13] [14] [15] [16] (Extended Data Fig. 1h, m) . PI3Kγ inhibition suppressed long-term growth and metastasis of spontaneous breast tumours, extended survival of mice with orthotopic breast tumours and enhanced the sensitivity of tumours to the nucleoside analogue gemcitabine ( To determine whether PI3Kγ directly regulates macrophage polarization, we analysed mRNA and protein expression in primary mouse macrophages stimulated in vitro with basal medium containing colony stimulating factor 1 (CSF-1) or in pro-inflammatory (IFNγ , lipopolysaccharide (LPS) and CSF-1) or anti-inflammatory (interleukin-4 (IL4) and CSF-1) conditions. Pro-inflammatory stimuli upregulated macrophage expression of innate immune proteins, cytokines and cell-surface receptors, whereas anti-inflammatory stimuli induced expression of immunosuppressive factors similar to those expressed in TAMs 1 (Extended Data Fig. 4a-c) . Genes and proteins associated with immune activation, antigen presentation and T cell activation were upregulated in Pik3cg −/− and PI3Kγ -inhibitor-treated macrophages (Fig. 2a-c and Extended Data Figs 4c-f, 5a-g). By contrast, genes associated with immune suppression and chemoattraction were inhibited (Fig. 2a-c and Extended Data Figs 4c-f, 5a-g). These results confirm that PI3Kγ controls a macrophage switch between immune stimulation and suppression.
To investigate how PI3Kγ regulates macrophage immune responses, we analysed the DNA-binding activities of NFκ B p65-RelA and the CCAAT/enhancer binding protein C/EBPβ in wild-type and Pik3cg-null macrophages, as NFκ B promotes expression of inflammatory , whereas C/EBPβ promotes expression of the immunosuppressive factor arginase 1 (Arg1, refs 19,20). PI3Kγ ablation rapidly and sustainably stimulated RelA DNA-binding activity in macrophages (Fig. 2d and Extended Data Fig. 5h ). By contrast, PI3Kγ ablation suppressed DNA-binding activity of C/EBPβ (Fig. 2e) . Consistent with these findings, PI3Kγ inhibition stimulated and sustained p65-RelA phosphorylation and simultaneously inhibited C/EBPβ and Akt phosphorylation (Fig. 2f, g and Extended Data Fig. 6a, b) .
Subsequently, we examined the effect of PI3Kγ inhibition on the stability and phosphorylation of proteins that activate NFκ B, including the TLR4-associated adaptor protein IRAK-1 and inhibitory κ B kinase β , IK Kβ , which promotes degradation of Iκ Bα , with subsequent release of NFκ B from an inhibitory Iκ B-NFκ B complex 18 . PI3Kγ deletion enhanced phosphorylation of IKKβ and TBK1 and degradation of IRAK-1 and Iκ Bα in LPS-stimulated Pik3cg −/− macrophages (Fig. 2h) . As an IK Kβ inhibitor suppressed the inflammatory phenotype observed in Pik3cg −/− macrophages (Fig. 2i) , these results indicated that PI3Kγ was both a feedback inhibitor of the TLR4-NFκ B activation pathway and a promoter of IL4 and C/EBPβ signalling. C/EBPβ has previously been linked with tumour immune suppression through its control of Arg1 expression 19, 20 . Expression of constitutively activated PI3Kγ (Pik3cgCAAX) 12 was sufficient to induce Arg1 expression in a manner that was inhibited by Cebpb, Mtor, or Rps6kb1 (also known as S6ka) knockdown (Extended Data Fig. 6c, d ). Both Cebpb knockdown and inhibition of S6Kα or mTOR by inhibitors suppressed expression of immune suppressive factors and stimulated expression of pro-inflammatory cytokines (Extended Data Fig. 6e-g ). These results show that PI3Kγ promotes immune suppression by activating mTOR-S6Kα -C/EBPβ and inhibiting NFκ B, thereby controlling a switch that regulates the balance between immune suppression and stimulation.
Since PI3Kγ blockade stimulated pro-inflammatory responses in macrophages, we investigated whether PI3Kγ blockade in macrophages promoted adaptive immunity. TAMs were isolated from wild-type and Pik3cg −/− tumours, mixed with tumour cells and adoptively transferred into new wild-type or Pik3cg −/− recipient mice (Fig. 3a) . Tumour growth was significantly inhibited (P = 0.01) in tumours containing Pik3cg −/− TAMs but not wild-type TAMs (Fig. 3b) . The number of 1,000 *P = 0.0005 −/− (n = 8 biological replicates) backgrounds (t-test). e, MHCII expression in wild-type or Pik3cg −/− TAMs. n = 3 biological replicates; P = 0.01 for both lung and breast tissue, as analysed by t-test. f, Fold change of mRNA expression in tumours and tumour-derived CD11b + cells from Pik3cg −/− and PI3Kγ -inhibitor-treated mice. n = 5 biological replicates; P < 0.01; t-test. g, Heat map of median-centred mRNA expression of genes involved in the immune response in tumours from wild-type and Pik3cg −/− mice. n = 3 biological replicates; P = 0.01; t-test. All experiments were performed two or more times. b, d, e, Data are shown as mean ± s.e.m.
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CD8
+ T cells was significantly increased (P = 0.0001) in tumours with Pik3cg −/− but not wild-type macrophages ( Fig. 3c and Extended Data Fig. 6h ), indicating that PI3Kγ signalling in TAMs inhibits CD8 + T cell recruitment to tumours. To determine whether macrophage-derived cytokines controlled tumour growth, we implanted tumour cells mixed with in vitro cultured macrophages or in conditioned medium from cultured macrophages into wild-type mice. Tumour growth was enhanced by IL4-stimulated wild-type macrophages and conditioned medium from wild-type macrophages, but inhibited by IL4-stimulated Pik3cg −/− macrophages and conditioned medium from Pik3cg
or PI3Kγ -inhibitor-treated macrophages and by all LPS-stimulated macrophages and conditioned medium from LPS-stimulated macrophages (Fig. 3d, e) . To determine which macrophage-derived immune factors affect tumour growth in vivo, we treated wild-type and
Pik3cg
−/− TAMs ex vivo with inhibitors of mTOR, Arginase1, IKKβ , IL12 or nitric oxide synthase 2 (NOS2) before mixing with tumour cells and implanting in mice (Extended Data Fig. 6i ). Blockade of mTOR or Arginase1 in wild-type macrophages suppressed tumour growth, while inhibition of NOS2, IL12 or IKKβ in Pik3cg −/− macrophages stimulated tumour growth. These results indicate that PI3Kγ -mTOR mediated immune suppression promotes tumour growth and that PI3Kγ inhibition reverses these effects by shifting macrophages towards NFκ Β -dependent pro-inflammatory polarization.
To investigate further whether macrophage PI3Kγ controlled tumour growth, mice bearing pre-established tumours were treated with PI3Kγ inhibitors in combination with clodronate liposomes, which deplete macrophages from tissues 21 . Separate PI3Kγ inhibitor and clodronate liposome treatment each partially inhibited tumour 
-16
Immune suppression, chemotattraction
Immune stimulation
Antigen presentation Fig. 8c-g ). T cells from Pik3cg −/− or PI3Kγ -inhibitor-treated mice expressed significantly more IFNγ and granzyme B (P = 0.001 and P < 0.03, respectively) and significantly less TGFβ 1 and IL10 protein (P = 0.008 and P = 0.03, respectively) and mRNA (P < 0.02) than T cells from wild-type mice ( Fig. 3j and Extended Data Fig. 8h-l) . Together, these results indicate that PI3Kγ inhibition in macrophages indirectly promotes both Th1 and cytotoxic adaptive immune responses.
To investigate whether PI3Kγ inhibition interacts with other immune therapies, we combined PI3Kγ and the checkpoint inhibitor anti-PD-1 in mouse tumour models. PD-L1, but not PD-L2, was expressed in macrophages in vitro and in vivo (Extended Data Fig. 9a, b) . PI3Kγ inhibition synergized with anti-PD-1 to suppress the growth of HPV +
HNSCC tumours in Pik3cg
−/− or inhibitor-treated male or female mice, inducing tumour regression in 86% of male and 90-100% of female mice, as well as continuous survival to date in 60% of male mice and 90-100% of female mice (Fig. 4a-c and Extended Data Fig. 9c, d) . Notably, PI3Kγ inhibition also synergized with anti-PD-1 to reduce tumour growth, extending survival and inducing tumour regression in 30% of mice bearing HPV − HNSCC (SCCVII) tumours (Fig. 4d-f and Extended Data Fig. 9e ). The combination of PI3Kγ and anti-PD-1 inhibitors activated T cell memory, as 100% of mice that WT −/− and/or Cd8 −/− mice. n = 6 biological replicates; P < 0.03, P < 0.001, as indicated; one-sided ANOVA with Tukey's post-hoc test. h, i, Weights of tumours implanted with naive or tumour-derived T cells (h, n = 8 biological replicates; P < 0.001; t-test) or inhibitor-treated T cells (i, n = 16 biological replicates; * P < 0.01; * * P < 0.0001; one-sided ANOVA with Tukey's post-hoc test). j, Protein concentrations of IFNγ (* P = 0.001; t-test) and granzyme B (P < 0.03, t-test) in tumours and T cells from wild-type and Pik3cg −/− mice (n = 3 biological replicates; NS, not significant). All data are shown as mean ± s.e.m. and all experiments were performed two or more times.
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had previously cleared HPV + tumours efficiently suppressed tumour growth when re-challenged with HPV + tumour cells and remained cancer-free (Extended Data Fig. 9f ). PI3Kγ and PD-1 inhibitors each stimulated immune response gene expression and inhibited immune suppressive gene expression, MHCII expression in TAMs and CD8 + T cell recruitment to tumours; and the combination of therapies further elevated these parameters (Fig. 4g-i and Extended Data Fig.  9g ). These studies showed that PI3Kγ inhibition can synergize with T-cell-targeted therapy to promote anti-tumour immune responses that induce sustained tumour regression in mouse models of cancer.
PI3Kγ -regulated immune responses might also affect outcome in cancer patients. We identified 43 PI3Kγ -regulated genes that are significantly (P < 0.05) associated with survival in the Cancer Genome Atlas HPV + HNSCC patients (Fig. 4j) . HPV + HNSCC patients (n = 34) with a low PI3Kγ -activity profile showed 100% survival at 3 years, compared to 56% survival for the remaining 63 patients (Fig. 4k) . In HPV − HNSCC patients, 39 of these genes were significantly (P < 0.05) shifted in the direction of high PI3Kγ activity, consistent with a pattern of pervasive immune suppression and reduced survival HLA_DRA  CD74  HLA_DQA2  CIITA  HLA_DOB  HLA_DRB5  HLA_DMB  HLA_DMA  MALT1  BTLA  ZBP1  LAG3  LAT  CD28  IFNG  GZMM  GZMH  GZMK  GZMA  CD8B  CD8A  CD4  IL12A  IL12B  CX3CR1  CXCR3  RASGRP1  CCR7  ADORA2A  IER3  ID2  CCL4  CCL7  IL6  CD276  IFIT1  F3  PLAU  HBEGF  PDGFB + HNSCC patients (n = 45 patients, P < 0.05; log-rank test). k, l, Multivariate PI3Kγ -regulated immune signature in HPV + HNSCC patients (k, n = 97; P < 0.001; log-rank test) and lung adenocarcinoma patients (l, n = 507; P < 0.001; log-rank test). All experiments were performed two or more times. a, d, h, Data are shown as mean ± s.e.m.
in HPV
− disease (Extended Data Fig. 10a) . In lung adenocarcinoma patients, 18 genes predicted survival; 202 patients with a low PI3Kγ -activity profile had 73% survival at 3 years, compared to 55% survival for 305 patients with a high PI3Kγ -activity profile (Fig. 4l) . These results suggest that a PI3Kγ -regulated immune suppression signature is associated with survival in cancer patients and that PI3Kγ inhibitors might provide clinical benefits for cancer patients.
Here we have shown that PI3Kγ regulates innate immunity during inflammation and cancer (Extended Data Fig. 10b, c) . Prior studies have implicated PI3Ks in the regulation of pro-inflammatory immune responses in macrophages, as pan-PI3K inhibitors and null mutations in the PI3Kγ effectors PDK1, Akt1 and TSC enhanced proinflammatory NFκ B-dependent transcription in macrophages [23] [24] [25] , while inhibition of PTEN and SHIP, which oppose PI3K function, promotes immune suppression 26, 27 . As macrophage reprogramming can enhance the activity of checkpoint inhibitors in cancer 5, 14, 22, 28 , our studies indicate that inhibitory targeting of macrophage signalling pathways may provide novel approaches to improve the long-term survival of cancer patients. Supplementary Information is available in the online version of the paper. 
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METHODS
Immune-related gene expression signature analysis in the Cancer Genome Atlas (TCGA) data. We analysed TCGA data for association between mRNA expression level of 16 candidate immune-related genes (ARG1, IL10, FOXP3, CD68, IL12A , IL12B, IFNG, CD8A, CD4, ITGAM (also known as CD11B), CD14, TNF, IL1A, IL1B, IL6 and CCL5) and 5 year overall survival. Illumina HiSeq RNaseqV2 mRNA expression and clinical data for 520 head and neck squamous cell carcinoma samples were downloaded from the TCGA data portal. Median follow-up from diagnosis was 1.8 years with a range of 0.01 years to 17.6 years. Follow-up time was truncated at 5-years for analysis and 200 deaths occurred in this period. For each of the 16 candidate immune response genes, we scored subjects as above (high) or below (low) the median expression and compared survival using a log-rank test at 5% significance. HPV + patients were stratified into a favourable immune profile if they had expression above the median for the significant genes IL12A, IL12B, IFNG, CD8A and below the median for IL6. Kaplan-Meier curves were plotted for these two groups. Similar methods were used to examine association of these 16 genes with 720 lung adenocarcinoma and 876 gastric carcinoma samples using the publically available data from KM Plotter 29 . In lung adenocarcinomas, 12 genes were significantly associated with survival; patients were scored as having a favourable immune profile if 7 or more of the 12 significant genes had expression in the favourable direction. In 876 gastric cancer samples, 8 genes were significantly associated with survival. Patients were scored as having a favourable immune profile if 5 out of the 8 genes had expression in the favourable direction. PI3Kγ-regulated gene expression signature analysis in TCGA data. We investigated 66 immune-related genes in four functional classes, 17 genes related to antigen presentation (HLA class I and II molecules), 24 genes surveying T cell activation, 20 innate immune response genes (IL6, CCL7 and others) and 5 genes related to cancer cell signalling. These genes changed expression in response to PI3Kγ inhibition for association with survival in HPV + and HPV − TCGA HNSCC and lung adenocarcinoma cohorts. Within each cancer type, we scored subjects as above or below the median expression for each gene and compared survival using a log-rank test, using 10% false discovery rate (FDR) within each class as the significance threshold. HPV + and HPV − HNSCC survival were investigated separately, as HPV − HNSCC generally has a worse prognosis. Within each cohort, patients were classified as having a favourable PI3Kγ immune response profile if they had expression levels above or below the median in the direction of low PI3Kγ activity for the genes identified as significant. We compared the survival experience of favourable versus less-favourable profiles of patients using Kaplan-Meier curves. Out of the 66 experimentally identified PI3Kγ -regulated genes, 43 showed significant association with overall survival in the HPV + cohort (FDR < 10% within each functional class). Comparison of these genes between HPV + and HPV − cohorts showed that HPV − samples generally had significantly (P < 0.05) lower expression of 42 genes in the antigen presentation and T cell activation classes, consistent with a pattern of adaptive immune suppression, and higher expression of genes in the innate immune response and cancer cell signalling classes, which were negatively associated with survival. Only MALT1 was not differentially expressed between the two groups (P = 0.7).
Mice. Pik3cg
−/− and Pik3cg −/− ,PyMT mice were generated as previously described 13 .
Cd8
−/− and Cd4 −/− mice with a C57Bl/6J background were purchased from the Jackson Laboratory and crossed with syngeneic Pik3cg −/− mice. All animal experiments were performed with approval from the Institutional Animal Care and Use Committee of the University of California. Animals were euthanized before the IACUC maximum allowable tumour burden of 2 cm 3 per mouse was exceeded. Tumour studies. Wild-type or Pik3cg −/− 6-8 week-old female or male syngeneic C57Bl/6J (LLC lung, PyMT breast and MEER HPV + HNSCC) or C3He/J (SSCVII HPV − HNSCC) mice were implanted with 10 6 tumour cells by subcutaneous injection (LLC, MEER, SCCVII) or by orthotopic injection (PyMT) (n = 10-15) and tumour growth was monitored for up to 30 days. Tumour dimensions were measured once when tumours were palpable. Tumour volumes were calculated using the equation (l 2 × w)/2. In some studies, wild-type and Pik3cg −/− mice with LLC tumours were treated with gemcitabine (150 mg kg −1 ) or saline by intraperitoneal (i.p.) injection on day 7 and day 14 (n = 10). LLC were acquired from ATCC, PyMT were from L. Ellies (University of California), HPV + MEER were from J. Lee (Cancer Biology Research Center, Sanford Research/USD) and SCCVII squamous carcinoma cells were from S. Schoenberger (La Jolla Institute for Allergy and Immunology). All cell lines were tested for mycoplasma and mouse pathogens and checked for authenticity against the International Cell Line Authentication Committee (ICLAC; http://iclac.org/databases/crosscontaminations/) list.
In some studies, mice bearing LLC, PyMT, HPV + MEER or HPV − HNSCC tumour cells were treated once daily by oral gavage with vehicle (5% NMP and 95% PEG 400), 15 mg kg −1 per day of the PI3Kγ inhibitor IPI-549 or by i.p. injection with 2.5 mg kg −1 twice per day of TG100-115 (ref. 13) beginning on day 8 post-tumour injection and continuing daily until euthanasia. IPI-549 is an orally bioavailable PI3Kγ inhibitor with a long plasma half-life and a K D value of 0.29 nM for PI3Kγ with > 58-fold weaker binding affinity for the other class I PI3K isoforms 17 . Enzymatic and cellular assays confirmed the selectivity of IPI-549 for PI3Kγ (> 200-fold in enzymatic assays and > 140-fold in cellular assays over other class I PI3K isoforms 17 ). To study the effect of IPI-549 on lung tumour growth, LLC tumour cells were passaged three times in C57BL/6 albino male mice. When tumour volume reached 1,500 mm 3 , tumours were collected and single-cell suspensions were prepared. This tumour cell suspension was implanted subcutaneously in the hind flank of C57BL/6 albino male mice at 10 6 cells per mouse. Prior to initiating treatment with once daily IPI-549 (15 mg kg −1 orally), groups were normalized on the basis of tumour volume. In some studies, wild-type-and Pik3cg −/− -tumour-bearing mice were treated with 100 μ g of anti-CD8 (clone YTS 169.4) or an isotype-control clone (LTF-2) from Bio X Cell administered by i.p. injections on day 7, 10 and 13 of tumour growth. For all tumour experiments, tumour volumes and weights were recorded at death. Anti-PD-1 tumour studies. C57Bl/6J (wild-type) or Pik3cg −/− 6-8 week-old male or female mice (MEER HPV + HNSCC) or C3He/J (SCCVII HPV − HNSCC) were implanted with tumour cells by subcutaneous injection (10 6 MEER or 10 5 SCCVII). In HPV + MEER studies, wild-type and Pik3cg −/− mice were treated with four doses of 250 μ g of anti-PD-1 antibody (clone RMP-14, Bio X Cell) or rat IgG2a isotype control (clone 2A3, Bio X Cell) every 3 days, starting when tumours became palpable on day 11 (n = 12-14 mice per group). Wild-type mice bearing HPV + tumours were also treated with the PI3Kγ inhibitor TG100-115 (ref. 13) twice per day by i.p. injection, beginning on day 11. Tumour regressions were calculated as a percentage of the difference in tumour volume between the date treatment was initiated and the first date of death of the control group. For HPV − SCCVII studies, C3He/J mice were treated with PI3Kγ inhibitor (2.5 mg kg −1 TG100-115 i.p.) beginning on day 6 post-tumour inoculation and with six doses of anti-PD-1 antibody (250 μ g clone RMP-14, Bio X Cell) or rat IgG2a isotype control (clone 2A3, Bio X Cell) every 3 days beginning on day 3 (n = 12 mice per group) or with a combination of the two. Alternatively, mice were treated with 5 mg kg −1 TG100-115 twice per day ± anti-PD-1 (250 μ g every 3 days) beginning on day 1 (Fig. 4) . ) or vehicle (5% NMP and 95% PEG 400) and anti-CSF-1R antibody (50 mg kg −1 i.p. 3× per week, clone AFS98, Bio X Cell) began on day 8 after tumour injection via oral gavage at a 5 ml kg −1 dose volume and continued daily for a total of 18 doses. Tumour-infiltrating myeloid cell analysis. Six-week-old female BALC/c mice were injected subcutaneously with 2.5 × 10 5 CT26 mouse colon carcinoma cells in 100 μ l PBS in the right flank. On day 8 after tumour injection, tumour-bearing mice were grouped and treated daily with IPI-549 (15 mg kg anti-CD115 (Bio X Cell clone AFS98) or 50 mg kg −1 rat IgG2a isotype control (Bio X Cell clone 2A3) antibodies as described above for a total of three injections. Two days after the final injection mice were euthanized, tumours were digested in a mixture of 0.5 mg ml −1 collagenase IV and 150 U ml −1 DNase I in RPMI-1640 for 30 min at 37 °C and tumour-infiltrating myeloid cells were analysed by flow cytometry.
In vivo macrophage adoptive transfer experiments. CD11b
+ Gr1 − cells were isolated from single-cell suspensions of LLC tumours from donor mice by LETTER RESEARCH fluorescence-activated cell sorting (FACS) or serial magnetic bead isolation. Additionally, for some experiments, primary bone-marrow-derived macrophages were polarized and collected into a single-cell suspension. Purified cells were admixed 1:1 with LLC tumour cells and 5 × 10 5 total cells were injected subcutaneously into new host mice. Tumour dimensions were measured three times per week beginning on day 7. In antibody blocking studies, CD11b
+
Gr1
− cells were incubated with 5 μ g anti-IL12 (clone RD1-5D9) or isotype (clone LTF-2, Bio X Cell) for 30 min before the addition of tumour cells. Mice were additionally treated intradermally with 5 μ g of antibody 3 and 6 days after tumour cell inoculation. In some studies, CD11b −/− mice (n = 8-10 per group). Tumour growth, intratumoral apoptosis and necrosis were investigated over 0-16 days. In other studies, wildtype T cells were incubated at 37 °C and 5% CO 2 for 6 h with 10 or 100 nM IPI-549 (Infinity Pharmaceuticals) or Cal-101 (Selleck Chem). After 6 h, T cells were washed, admixed 1:1 with LLC tumour cells, and 10 6 total cells were injected subcutaneously into recipient mice. Tumour growth was monitored for 14 days. Isolation of single cells from mouse tumours. Tumours were isolated, minced in a Petri dish on ice and then enzymatically dissociated in Hanks balanced salt solution containing 0.5 mg ml −1 collagenase IV (Sigma), 0.1 mg ml −1 hyaluronidase V (Sigma), 0.6 U ml −1 dispase II (Roche) and 0.005 MU ml −1 DNase I (Sigma) at 37 °C for 5-30 min. The duration of enzymatic treatment was optimized for greatest yield of live CD11b + cells per tumour type. Cell suspensions were filtered through a 70-μ m cell strainer. Red blood cells were solubilized with red cell lysis buffer (Pharm Lyse, BD Biosciences) and the resulting suspension was filtered through a cell strainer to produce a single-cell suspension. Cells were washed once with PBS before use in flow cytometry analysis or magnetic bead purification. Peritoneal macrophage isolation. Thioglycollate-elicited peritoneal macrophages were collected 96 h after i.p. injection of a 3% thioglycollate solution. Cells were collected from the peritoneal cavity in 10 ml of PBS and macrophage enrichment was performed by plating cells in RPMI with 10% FBS and 1% penicillin/ streptomycin for 2 h at 37 °C and 5% CO 2 . After 2 h, non-adherent cells were removed with three PBS washes, and cells were analysed via flow cytometry and qPCR analysis. Flow cytometry staining and analysis. Single-cell suspensions (10 6 cells in 100 μ l total volume) were incubated with aqua live dead fixable stain (Life Technologies), FcR-blocking reagent (BD Biosciences) and fluorescently labelled antibodies and incubated at 4 °C for 1 h. Primary antibodies to cell surface markers directed against F4/80 (BM8), CD45 (30-F11), CD11b (M1/70), Gr1 (RB6-8C5), CD3 (145-2C11), CD4 (GK1.5), CD8 (53-6.7), CD273 (B7-DC), CD274 (B7-H1) were from eBioscience; Ly6C (AL-21), Ly6G (1A8), CD11c (HL3), and MHC-II (AF6-120.1) from BD Pharmingen, CCR2 (475301) from R&D Systems and CD206 (MR5D3) from AbD Serotech. For intracellular staining, cells were fixed, permeabilized using transcription factor staining buffer set (eBioscience) and then incubated with fluorescently labelled antibodies to FoxP3 (FJK-16 s) from eBioscience. Multicolour FACS analysis was performed on a BD Canto RUO 11 colour analyser. All data analysis was performed using the flow cytometry analysis program FloJo (Treestar). Magnetic bead purification of myeloid cells. Single-cell preparations from bone marrow or tumours were incubated with FcR-blocking reagent (BD Biosciences) and then with 20 μ l magnetic microbeads conjugated to antibodies against CD11b, Gr1, CD90.2, CD4 and CD8 (Miltenyi Biotech MACS Microbeads) per 10 7 cells for 20 min at 4 °C. Cells bound to magnetic beads were then removed from the cell suspension according to the manufacturer's instructions. 
− cells. CD11b-positive cells were defined by increased staining over the isotype control, and Gr1 levels were defined both by comparison to the isotype control and relative staining to other populations. Mouse macrophage differentiation and culture. Bone-marrow-derived cells were aseptically collected from 6-8 week-old female mice by flushing leg bones of euthanized mice with PBS, 0.5% BSA, 2 mM EDTA, incubating in red cell lysis buffer (155 mM NH 4 Cl, 10 mM NaHCO 3 and 0.1 mM EDTA) and centrifuging over Histopaque 1083 to purify the mononuclear cells. Approximately 5 × 107 bone-marrow-derived cells were purified by gradient centrifugation from the femurs and tibias of a single mouse. Purified mononuclear cells were cultured in RPMI + 20% serum + 50 ng ml −1 mCSF (PeproTech). Human macrophage differentiation and culture. Human leukocytes from apheresis blood products were obtained from the San Diego Blood Bank. Cells were diluted in PBS, 0.5% BSA, 2 mM EDTA, incubated in red cell lysis buffer (155 mM NH 4 Cl, 10 mM NaHCO 3 and 0.1 mM EDTA) and centrifuged over Histopaque 1077 to purify mononuclear cells. Approximately 10 9 bone-marrow-derived cells were purified by gradient centrifugation from one apheresis sample. Purified mononuclear cells were cultured in RPMI + 20% serum + 50 ng ml −1 Human mCSF (PeproTech). Non-adherent cells were removed after 2 h by washing and adherent cells were cultured for 6 days to differentiate macrophages fully. Macrophage polarization. Bone-marrow-derived macrophages were polarized with IFNγ (20 ng ml −1 , Peprotech) + LPS (100 ng ml −1 , Sigma) or LPS alone for 24 h, or IL4 (20 ng ml , Peprotech) for 24-48 h. For inhibitor studies, PI3Kγ inhibitors (1 μ M) (IPI-549, Infinity Pharmaceuticals and TG100-115, Targegen/ Sanofi-Aventis), rapamycin (10 μ M, Selleck), or ML120B (30 μ M) were incubated with macrophages 1 h before the addition of polarizing stimuli. Total RNA was harvested from macrophages using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA sequencing. Freshly isolated mouse bone marrow cells from nine wildtype and nine Pik3cg −/− mice were pooled into three replicates sets of wild-type or Pik3cg
−/− cells and differentiated into macrophages for 6 days in RPMI + 20% FBS+ 1% penicillin/streptomycin + 50 ng ml −1 mCSF. Each replicate set of macrophages was then treated with mCSF, IL4 or IFNγ /LPS. Macrophages were removed from dishes, and RNA was collected using Qiagen Allprep kit. In addition, RNA was harvested from day 14 (500 mm 
Gr1-F480
+ TAMs from wild-type (C57BL/6) and Pik3cg −/− mice. RNA was collected using the Qiagen Allprep kit. RNA libraries were prepared from 1 μ g RNA per sample for sequencing using standard Illumina protocols. RNA sequencing was performed by the University of California, San Diego Institute for Genomic Medicine. mRNA profiles were generated by single read deep sequencing, in triplicate, using Illumina HiSeq2000. Sequence analysis. Sequence analysis was performed as previously described 16 . Sequence files from Illumina HiSeq that passed quality filters were aligned to the mouse transcriptome (mm9 genome build) using the Bowtie2 aligner4. Genelevel count summaries were analysed for statistically significant changes using DESeq. Individual P values were adjusted for multiple testing by calculating Storey's q values using fdrtooltrimmer. For each gene, the q value is the smallest false discovery rate at which the gene is found significant. We analysed biological processes as defined by the Gene Ontology Consortium. Each gene ontology term defines a set of genes. The entire list of genes, sorted by the q value in ascending order, was subjected to a non-parametric variant of the gene set enrichment analysis (GSEA), in which the parametric Kolmogorov-Smirnov P value was replaced with the exact rank-order P value. We perform a Bonferroni adjustment of gene set P values for the number of gene sets tested. Heat maps of expression levels were created using in-house hierarchical clustering software that implements Ward clustering. The colours qualitatively correspond to fold changes. Individual quantitative RT-PCR. cDNA was prepared using 1 μ g RNA with the qScript cDNA Synthesis Kit (Quanta Biosciences). Sybr green-based qPCR was performed using human and mouse primers to Arg1, Ifng, Il10, Il12p40, Il1b, Il6, Ccl2, Vegfa, Gapdh, Nos2, Tgfb1, Tnfa and mouse H2-Aa, H2-Ab1, H2-Eb1, and H60a (Qiagen QuantiTect Primer Assay). mRNA levels were normalized to Gapdh ∆ = − C C C ( ) 
siRNA-mediated knockdown and gene transfection. Freshly isolated bonemarrow-derived CD11b
+ myeloid cells or differentiated macrophages were transfected by electroporation using an AMAXA mouse macrophage nucleofection kit with 100 nM of siRNA or 2 μ g Pik3cgCAAX or pcDNA control plasmid. Nonsilencing (Ctrl_AllStars_1) siRNA and Cebpb (MmCebpb_4 and MmCebpb_6), and Mtor (Mm_Frap1_1 and Mm_Frap1_2) siRNAs were purchased from Qiagen. After transfection, cells were cultured for 36-48 h in RPMI containing 10% serum and 10 ng ml −1 mCSF (PeproTech) or polarized as described above. ELISA assays. Whole tumours, CD11b
+
Gr1
− cells, CD90.2 + cells, CD4 + cells and CD8 + cells isolated from LLC tumours were lysed in RIPA buffer and total protein concentrations were determined using a BCA protein assay (Pierce). Macrophage supernatants (100 μ l) or 500 μ g of total protein lysate from tumours were used in ELISAs to detect CCL2, TGFβ , IL1β , TNFα , IL6, IFNγ , IL10, IL12 and granzyme B
